Clin Infect Dis:他汀增加流感疫苗接种者流感风险?想多了

2018-08-17 吴星 环球医学

2018年7月,美国和西班牙学者在《Clin Infect Dis》发表一项研究,考察了他汀使用与2010~2015年接种标准剂量或高剂量流感疫苗的使用Medicare医疗保险的老年人流感相关结局的风险之间的相关性。

2018年7月,美国和西班牙学者在《Clin Infect Dis》发表一项研究,考察了他汀使用与2010~2015年接种标准剂量或高剂量流感疫苗的使用Medicare医疗保险的老年人流感相关结局的风险之间的相关性。

背景:他汀用于降低血管疾病风险。最近的研究表明,他汀使用可能与流感疫苗接种者流感风险的增加相关。研究者使用Medicare数据,评估了他汀与疫苗接种者流感相关结局风险的相关性。

方法:在这项回顾性队列研究中,研究者鉴别出>65岁的Medicare受益人,这些受益人从2010~2011到2014~2015年在药房接种了高剂量(HD)或标准剂量(SD)流感疫苗。他汀使用者与非使用者根据疫苗类型、人口统计学特征、既往医疗就诊、合并症进行配对。研究者使用多变量泊松模型评估疫苗接种前后使用他汀与流感相关结局之间的相关性。研究结局包括流感高发期流感相关诊室就诊(奥司他韦调配后进行快速测试)和流感相关住院(包括急诊)。

结果:研究纳入了1403651名他汀使用者和配对的非使用者。队列很好的平衡,所有测量协变量的标准平均差≤0.03。对于他汀使用者vs不使用者,流感相关就诊和流感相关住院的调整相对风险分别为1.086(95% 置信区间[CI],1.025~1.150)和1.096(95% CI,1.013~1.185)。流感相关就诊的风险差范围从-0.02到0.23,流感相关住院为-0.04到0.13,这取决于流感季严重度。HD和SD疫苗,以及非合成和合成他汀使用者间,结果相似。

结论:280万Medicare受益人中,这些结果表明,老年人疫苗接种前后使用他汀基本不会影响流感相关医疗就诊风险。

原始出处:

Izurieta HS, Chillarige Y, Kelman JA, et.al. Statin Use and Risks of Influenza-Related Outcomes Among Older Adults Receiving Standard-Dose or High-Dose Influenza Vaccines Through Medicare During 2010-2015. Clin Infect Dis. 2018 Jul 18;67(3):378-387. doi: 10.1093/cid/ciy100.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1998505, encodeId=393d199850546, content=<a href='/topic/show?id=20a95669854' target=_blank style='color:#2F92EE;'>#接种者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56698, encryptionId=20a95669854, topicName=接种者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Fri Mar 29 09:43:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012779, encodeId=04492012e79b8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Mar 22 08:43:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019515, encodeId=e3d92019515dd, content=<a href='/topic/show?id=dbba65336b1' target=_blank style='color:#2F92EE;'>#流感疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65336, encryptionId=dbba65336b1, topicName=流感疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Wed Jan 16 23:43:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341177, encodeId=264f3411e73d, content=哈哈哈,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1ee1608797, createdName=huangshang9812, createdTime=Mon Aug 27 14:28:49 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257855, encodeId=d8fe125e855ac, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sun Aug 19 03:43:00 CST 2018, time=2018-08-19, status=1, ipAttribution=)]
    2019-03-29 mhm289
  2. [GetPortalCommentsPageByObjectIdResponse(id=1998505, encodeId=393d199850546, content=<a href='/topic/show?id=20a95669854' target=_blank style='color:#2F92EE;'>#接种者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56698, encryptionId=20a95669854, topicName=接种者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Fri Mar 29 09:43:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012779, encodeId=04492012e79b8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Mar 22 08:43:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019515, encodeId=e3d92019515dd, content=<a href='/topic/show?id=dbba65336b1' target=_blank style='color:#2F92EE;'>#流感疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65336, encryptionId=dbba65336b1, topicName=流感疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Wed Jan 16 23:43:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341177, encodeId=264f3411e73d, content=哈哈哈,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1ee1608797, createdName=huangshang9812, createdTime=Mon Aug 27 14:28:49 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257855, encodeId=d8fe125e855ac, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sun Aug 19 03:43:00 CST 2018, time=2018-08-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1998505, encodeId=393d199850546, content=<a href='/topic/show?id=20a95669854' target=_blank style='color:#2F92EE;'>#接种者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56698, encryptionId=20a95669854, topicName=接种者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Fri Mar 29 09:43:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012779, encodeId=04492012e79b8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Mar 22 08:43:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019515, encodeId=e3d92019515dd, content=<a href='/topic/show?id=dbba65336b1' target=_blank style='color:#2F92EE;'>#流感疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65336, encryptionId=dbba65336b1, topicName=流感疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Wed Jan 16 23:43:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341177, encodeId=264f3411e73d, content=哈哈哈,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1ee1608797, createdName=huangshang9812, createdTime=Mon Aug 27 14:28:49 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257855, encodeId=d8fe125e855ac, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sun Aug 19 03:43:00 CST 2018, time=2018-08-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1998505, encodeId=393d199850546, content=<a href='/topic/show?id=20a95669854' target=_blank style='color:#2F92EE;'>#接种者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56698, encryptionId=20a95669854, topicName=接种者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Fri Mar 29 09:43:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012779, encodeId=04492012e79b8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Mar 22 08:43:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019515, encodeId=e3d92019515dd, content=<a href='/topic/show?id=dbba65336b1' target=_blank style='color:#2F92EE;'>#流感疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65336, encryptionId=dbba65336b1, topicName=流感疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Wed Jan 16 23:43:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341177, encodeId=264f3411e73d, content=哈哈哈,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1ee1608797, createdName=huangshang9812, createdTime=Mon Aug 27 14:28:49 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257855, encodeId=d8fe125e855ac, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sun Aug 19 03:43:00 CST 2018, time=2018-08-19, status=1, ipAttribution=)]
    2018-08-27 huangshang9812

    哈哈哈,学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1998505, encodeId=393d199850546, content=<a href='/topic/show?id=20a95669854' target=_blank style='color:#2F92EE;'>#接种者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56698, encryptionId=20a95669854, topicName=接种者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Fri Mar 29 09:43:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012779, encodeId=04492012e79b8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Mar 22 08:43:00 CST 2019, time=2019-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019515, encodeId=e3d92019515dd, content=<a href='/topic/show?id=dbba65336b1' target=_blank style='color:#2F92EE;'>#流感疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65336, encryptionId=dbba65336b1, topicName=流感疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Wed Jan 16 23:43:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341177, encodeId=264f3411e73d, content=哈哈哈,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1ee1608797, createdName=huangshang9812, createdTime=Mon Aug 27 14:28:49 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257855, encodeId=d8fe125e855ac, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sun Aug 19 03:43:00 CST 2018, time=2018-08-19, status=1, ipAttribution=)]

相关资讯

他汀+阿司匹林,一对儿好搭档

他汀稳定斑块,不让易损斑块发生破裂;阿司匹林抑制血小板,使得血液变稀,一旦发生了斑块破裂,不容易形成血栓,或者血栓形成得少了,两者协同作用,防止发生血栓性的血管事件,如心肌梗死、脑梗死和血管性死亡。

Circulation:他汀和PCSK9联合治疗的患者的残余炎症风险

他汀类药物联合PCSK9(9型前体蛋白转化酶枯草杆菌蛋白酶/kexin)抑制可显著降低低密度脂蛋白(LDL-C)和心血管事件率。目前尚不明确,在治疗后,以高灵敏度的C反应蛋白(hsCRP)所衡量的残余炎症风险是否仍是此类患者的重要临床问题。研究人员在参与SPIRE-1和SPIRE-2心血管预后试验的采用他汀和bococizumab联合治疗的9738位患者中,根据治疗14周时检测的hsCRP和LDL

服用他汀类降脂药有什么注意事项?

他汀类药物是羟甲基戊二酰辅酶A还原酶抑制剂,也就是胆固醇合成酶的抑制剂,可抑制胆固醇和甘油三酯的合成和分泌,为目前临床上应用最广泛的一类降脂药。由于这类药物的英文名称均含有“statin”,故简称为他汀类。包括阿托伐他汀、瑞舒伐他汀、洛伐他汀、辛伐他汀、普伐他汀、氟伐他汀。

Alirocumab联合他汀类药物治疗可降低糖尿病患者的心脏事件风险

根据美国糖尿病协会第78届科学会议(ADA)提供的一项研究,患有2型糖尿病合并急性冠脉综合征(ACS)的患者可以从他汀类药物和Alirocumab治疗中获益

Eur Heart J:二级预防 他汀和非他汀类降LDL药对心血管结局有何影响?

发表于《Eur Heart J》上的一项随机试验的meta分析,考察了在二级预防中,他汀和非他汀类降LDL药对心血管结局的影响。

甘油三酯增高该咋办?

很多人化验血时发现甘油三酯增高,应该咋办呢?以下是几个关键信息。